LACTULOSE For Oral Solution

Manufacturer
Cumberland Assured Products Inc.
Effective date
2025-09-01
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 21:41:37

Label at a glance#

ProductLACTULOSE Crystalline
Active ingredientlactulose
Label structure16 sections

Indications and uses

LACTULOSE For Oral Solution is indicated for the treatment of constipation. In patients with a history of chronic constipation, lactulose therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

Dosage and administration

The usual adult dosage is 10 g to 20 g of lactulose daily. The dose may be increased to 40 g daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

DESCRIPTION SECTION

LACTULOSE is a synthetic disaccharide in the form of crystals for reconstitution prior to use for oral administration Each 10 g of lactulose contains less than 0.3 g galactose and lactose as a total sum. The pH range is 3.0 to 7.0.

Lactulose is a colonic acidifier which promotes laxation.

The chemical name for lactulose is 4-O-β-D-Galactopyranosyl-D-fructofuranose. It has the following structural formula:

Structural Formula
Structural Formula

The molecular formula is C12H22O11. The molecular weight is 342.30.
It is freely soluble in water.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

LACTULOSE For Oral Solution is poorly absorbed from the gastro-intestinal tract and no enzyme capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue. As a result, oral doses of lactulose reach the colon virtually unchanged. In the colon, lactulose is broken down primarily to lactic acid, and also to small amounts of formic and acetic acids, by the action of colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This in turn causes an increase in stool water content and softens the stool.

Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be slow, 24 to 48 hours may be required to produce desired bowel movement.

Lactulose given orally to man and experimental animals resulted in only small amounts reaching the blood. Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

LACTULOSE For Oral Solution is indicated for the treatment of constipation. In patients with a history of chronic constipation, lactulose therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Since LACTULOSE For Oral Solution contains galactose (less than 0.3 g/10 g as a total sum with lactose), it is contraindicated in patients who require a low galactose diet.

WARNINGS

WARNINGS SECTION

A theoretical hazard may exist for patients being treated with lactulose who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H2 gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO2 as an additional safeguard may be pursued but is considered to be a redundant measure.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Since LACTULOSE For Oral Solution contains galactose and lactose (less than 0.3 g/10 g as a total sum), it should be used with caution in diabetics.

Information for Patients

INFORMATION FOR PATIENTS SECTION

In the event that an unusual diarrheal condition occurs, contact your physician.

Laboratory Tests

LABORATORY TESTS SECTION

Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.

Drug Interactions

DRUG INTERACTIONS SECTION

Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility.

There are no known animal data on long-term potential for mutagenicity.

Administration of lactulose syrup in the diet of mice for 18 months in concentrations of 3 and 10 percent (v/w) did not produce any evidence of carcinogenicity.

In studies in mice, rats, and rabbits, doses of lactulose syrup up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Reproduction studies have been performed in mice, rats, and rabbits at doses up to 3 or 6 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Precise frequency data are not available.

Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia.

Nausea and vomiting have been reported.

OVERDOSAGE

OVERDOSAGE SECTION

Signs and Symptoms

SPL UNCLASSIFIED SECTION

There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated.

Oral LD50

SPL UNCLASSIFIED SECTION

The acute oral LD50 of the drug is 48.8 mL/kg in mice and greater than 30 mL/kg in rats.

Dialysis

SPL UNCLASSIFIED SECTION

Dialysis data are not available for lactulose. Its molecular similarity to sucrose, however, would suggest that it should be dialyzable.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The usual adult dosage is 10 g to 20 g of lactulose daily. The dose may be increased to 40 g daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement.

DIRECTIONS FOR PREPARATION

SPL UNCLASSIFIED SECTION

Dissolve contents of packet in half a glass (4 ounces) of water.

When LACTULOSE For Oral Solution is dissolved in water, the resulting solution may be colorless to a slightly pale yellow color.

HOW SUPPLIED

HOW SUPPLIED SECTION

LACTULOSE For Oral Solution is available in single dose packets of 10 g (NDC 85592-819-01) and single dose packets of 20 g (NDC 85592-829-01). The packets are supplied as follows:

  • NDC 85592-819-30
    (Carton of thirty 10 g packets)

  • NDC 85592-829-30
    (Carton of thirty 20 g packets)

STORE AT ROOM TEMPERATURE, 15°-30°C (59°-86°F).

To report SUSPECTED ADVERSE REACTIONS, contact Cumberland Assured Products Inc. at 1-615-564-2189 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Manufactured for:
CUMBERLAND ASSURED PRODUCTS INC.
Nashville, TN 37203
Issued: July 2025

Principal Display Panel - 10 g Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 85592-819-30

crystalline

Lactulose
For Oral Solution

10 Grams 30 Single Dose Packets

CUMBERLAND ASSURED PRODUCTS

Rx only

Principal Display Panel - 10 g Carton Label
Principal Display Panel - 10 g Carton Label

Principal Display Panel - 10 g Pouch Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 85592-819-01

crystalline

Lactulose
For Oral Solution

10 Grams

Single Dose Packet

Rx only

Principal Display Panel - 10 g Pouch Label
Principal Display Panel - 10 g Pouch Label

Principal Display Panel - 20 g Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 85592-829-30

crystalline

Lactulose
For Oral Solution

20 Grams 30 Single Dose Packets

CUMBERLAND ASSURED PRODUCTS

Rx only

Principal Display Panel - 20 g Carton Label
Principal Display Panel - 20 g Carton Label

Principal Display Panel - 20 g Pouch Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 85592-829-01

crystalline

Lactulose
For Oral Solution

20 Grams

Single Dose Packet

Rx only

Principal Display Panel - 20 g Pouch Label
Principal Display Panel - 20 g Pouch Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1251190lactulose 10 GM Powder for Oral SolutionPSN2
1251194lactulose 20 GM Powder for Oral SolutionPSN2
1251190lactulose 10000 MG Powder for Oral SolutionSCD2
1251194lactulose 20000 MG Powder for Oral SolutionSCD2
1251190lactulose 10 GM Granules for Oral SolutionSY2
1251190lactulose 10 GM Powder for Oral SolutionSY2
1251194lactulose 20 GM Granules for Oral SolutionSY2
1251194lactulose 20 GM Powder for Oral SolutionSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
LACTULOSE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeCode 128(01)20385592819303GTIN-14: 20385592819303
GTIN storage (14 digits): 20385592819303
lac0c-0002-02.jpg
BarcodeEAN-130385592819019GTIN-13: 0385592819019
EAN-13: 0385592819019
GTIN-12: 385592819019
UPC-A: 385592819019
GTIN storage (14 digits): 00385592819019
lac0c-0002-03.jpg
BarcodeEAN-130385592829018GTIN-13: 0385592829018
EAN-13: 0385592829018
GTIN-12: 385592829018
UPC-A: 385592829018
GTIN storage (14 digits): 00385592829018
lac0c-0002-05.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
13620a32-e3b4-4aad-8280-283dce30ddffProduct name120260105
27883b46-af31-44b0-b4ce-e6b4f6d825a7Product name420250812
c1a80c95-0e51-52a0-75fa-75808f51ded8Product name220150421

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
85592-819-01LACTULOSE Crystalline10 g in 1 POUCHPOWDER, FOR SOLUTION102
85592-819-30LACTULOSE Crystalline30 in 1 CARTONPOWDER, FOR SOLUTION302
85592-829-01LACTULOSE Crystalline20 g in 1 POUCHPOWDER, FOR SOLUTION202
85592-829-30LACTULOSE Crystalline30 in 1 CARTONPOWDER, FOR SOLUTION302

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
85592-819-01EA - Each85592-819d85656e3-f129-42d5-81a1-ae041ef7a20a12025-12-16
85592-819-30EA - Each85592-819d6000af8-6ac9-496e-854a-b721e95511da12025-12-16
85592-829-01EA - Each85592-829558a389e-2eb6-438f-8bdf-52f40398a7ce12025-12-16
85592-829-30EA - Each85592-829addb74f5-b767-4011-8f64-9e827def071612025-12-16

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
85592-81985592-819-01, 85592-819-30
85592-82985592-829-01, 85592-829-30

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Name, UNII, Kind table
NameUNIIKind
lactulose9U7D5QH5AEACTIB
lactulose9U7D5QH5AEACTIB

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A074712-001LACTULOSELACTULOSE10GM/PACKETFOR SOLUTION / ORALAARS1997-12-10
A074712-002LACTULOSELACTULOSE20GM/PACKETFOR SOLUTION / ORALAARS1997-12-10

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
A074712-001AA
A074712-002AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 88 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAARS1997-12-10c2088c7a36db…
2026-10-15 13:18:302026-09A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAARS1997-12-10c2088c7a36db…
2026-09-14 22:38:342026-08A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAARS1997-12-1084e616aacf4f…
2026-09-14 22:38:342026-08A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAARS1997-12-1084e616aacf4f…
2026-08-18 06:07:402026-07A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAARS1997-12-10caaa826d4ba7…
2026-08-18 06:07:402026-07A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAARS1997-12-10caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAARS1997-12-10011fe1cb6892…
2026-02-19 14:30 UTC2026-02A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAARS1997-12-10011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAARS1997-12-1031067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAARS1997-12-1031067a03dcf5…
2025-08-23 18:47 UTC2025-08A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALAARS1997-12-106a471c1ec25d…
2025-08-23 18:47 UTC2025-08A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALAARS1997-12-106a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-10fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-10fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-10b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-10b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-1003ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-1003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-102680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-102680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-105bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-105bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-10d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-10d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-10d06236e962d9…
2024-10-29 15:01 UTC2024-10A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-10d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-1079d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-1079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-10301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-10301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-101e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-101e350fbaab3a…
2024-05-31 18:47 UTC2024-05A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-108072bd15b7f6…
2024-05-31 18:47 UTC2024-05A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-108072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-105c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-105c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-105d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-105d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074712-001LACTULOSE10GM/PACKETFOR SOLUTION / ORALRS1997-12-104b0b4de00fa7…
2022-04-04 05:41 UTC2022-04A074712-002LACTULOSE20GM/PACKETFOR SOLUTION / ORALRS1997-12-104b0b4de00fa7…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09A074712-001AA1c2088c7a36db…
2026-10-15 13:18:302026-09A074712-002AA1c2088c7a36db…
2026-09-14 22:38:342026-08A074712-001AA184e616aacf4f…
2026-09-14 22:38:342026-08A074712-002AA184e616aacf4f…
2026-08-18 06:07:402026-07A074712-001AA1caaa826d4ba7…
2026-08-18 06:07:402026-07A074712-002AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074712-001AA1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A074712-002AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074712-001AA131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074712-002AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A074712-001AA16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A074712-002AA16a471c1ec25d…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A074712-001AA1a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A074712-002AA1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
LACTULOSE CrystallineLACTULOSECumberland Assured Products Inc.59e75426-42ae-4904-941f-009181101a8a2025-09-01Warnings, Adverse reactionsExact identifier
ndc (package): 85592-829-01
ndc (package): 85592-829-30
ndc (package): 85592-819-30
ndc (package): 85592-819-01
ndc (product): 85592-819
ndc (product): 85592-829
ndc11 (package): 85592082901
ndc11 (package): 85592082930
ndc11 (package): 85592081901
ndc11 (package): 85592081930
spl id: ef4e6e26-7b7d-4c48-8cc8-c101cc24d6f9
spl set id: 59e75426-42ae-4904-941f-009181101a8a

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.